Healius

Digital Automation And Genomics Expansion Will Support A Stronger Long Term Pathology Business

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

04 Dec 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-29.1%

-0.5%

-29.1%

-0.5%

You can edit this narrative until Dec 5 4:20 AM. Then, changes will post as Updates.

Author's Valuation

AU$0.98.0% overvalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

AU$0.9

8.0% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

4.28%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.33%

Calculation

AU$32.72m

Earnings '28

20.09x

PE Ratio '28

AU$657.13m

Market Cap '28

AU$657.13m

Market Cap '28

726.13m

No. shares '28

AU$0.90

Share Price '28

AU$0.90 Share Price '28

Discounted to 2025 @ 0.07% p.a.

AU$0.90

Fair Value '25